One data platform just gave shareholders a clean exit after landing an all-cash takeover offer. One investing giant is starting to look different under new leadership, while one beaten-down pharma name is trying to turn its weight-loss pill into a global growth story. We’ll show you where to take gains and where the buy case still looks alive.
Top Picks (Sponsored)
Only a tiny percentage of stocks meet the criteria for this report.
Analysts have released a new edition highlighting seven names selected using multiple indicators.
Recent picks have delivered notable short-term gains, though results can vary.
The latest report is now available for a limited time.
Download the free report today.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
Futures at a Glance📈
Futures are sliding after last week’s record run, with rising oil and higher long-term bond yields putting pressure back on tech. Traders are now looking to Nvidia and big retail earnings to see whether this rally still has enough fuel to push through the latest rate scare.
Want to make sure you never miss a pre-market alert?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.
Email’s great. Texts are faster.
You’ll be first in line when the market starts moving.
What to Watch
Earnings (Premarket):
• Baidu, Inc. [BIDU]
• Ryanair Holdings plc [RYAAY]
• Brady Corporation [BRC]
• ReNew Energy Global plc [RNW]
• iQIYI, Inc. [IQ]
Earnings (Aftermarket):
• XP Inc. [XP]
• Agilysys, Inc. [AGYS]
• Yalla Group Limited [YALA]
Fed Speakers:
• Atlanta Fed First Vice President Cheryl Venable welcoming remarks: 8:30 am
Elite Trade Club Insider
More Than $800 Million Just Headed For The Exit
A major holder sold nearly $496 million worth of stock in a cloud software name after a 410% one-year run, while another asset management stock saw more than $320 million in insider-linked selling near its 52-week high.
This may only look like two big sales to you, but Elite Trade Club Insider readers will see where major holders are using strong markets to cash out after the easy money has already been made.
You’re reading the free version. Here’s what we held back.
Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.
A subscription gets you:
The insider buys, options bets, and dark pool moves the free edition can't show you. Unlocked every weekday.
A Sunday Deep Dive that tells you where to look before Monday's bell rings.
The Friday Smart Money Brief: who bought, who sold, where the big options bets landed, and where institutions are hiding volume. Three data layers. One email.
A Monthly Insider Scorecard so you always know whether smart money is buying or selling the market.
Every past Insider edition, unlocked, on elitetrade.club. Go back and see what you missed.
$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.
Data & Advertising
LiveRamp Holdings Gets the Buyout Premium Investors Were Waiting For
LiveRamp Holdings Inc (NYSE: RAMP) finally got the kind of strategic exit that makes sense for a data collaboration platform in an AI-driven advertising market. Publicis agreed to acquire the company in an all-cash deal worth $2.5 billion, paying $38.50 per share, a 29.8% premium to LiveRamp’s May 15 closing price.
The logic is clear. Publicis wants deeper data and AI capabilities as advertisers try to navigate a more fragmented media landscape.
LiveRamp gives it more identity, data collaboration, and measurement infrastructure at a time when brands are under pressure to improve targeting without relying on older digital tracking models. That makes the deal more than just a takeout. It shows that first-party data infrastructure still has strategic value.
For LiveRamp shareholders, the upside now looks mostly capped by the deal price. The stock jumped about 26% premarket to roughly $37.30, leaving limited spread to the $38.50 offer. Unless a competing bidder emerges, this is now more of a merger-arbitrage setup than a fresh growth stock story.
My Take For You: LiveRamp earned the premium because its data platform fits exactly where advertising is going. But after the pop, most of the easy money has already been made.
My Verdict: Take the gain. The risk is that deal timing, regulatory review, or lack of a higher bid leaves little reason to chase the stock near the offer price.
Conglomerates
Berkshire Hathaway Enters the Greg Abel Era With a Portfolio Shake-Up
Berkshire Hathaway Inc Class B (NYSE: BRK.B) is starting to look different under Greg Abel. In his first three months as CEO, Berkshire made one of its biggest portfolio renovations in years, adding new stakes in Delta Air Lines and Macy’s, increasing several holdings, and more than tripling its position in Alphabet.
That Alphabet move lifted the holding by 224% in the first quarter and made it Berkshire’s seventh-largest equity position by market value at the time.
The bigger message is that Abel is not just maintaining the portfolio he inherited. Berkshire eliminated a long list of positions, including Visa, Mastercard, UnitedHealth, Domino’s, Aon, Amazon, Charter, Diageo, and others.
Chevron was the largest cut by market value, with Berkshire reducing the stake by 35%, while Apple was left unchanged and Bank of America was trimmed by less than 1%.
That shift matters because Berkshire’s identity has always been tied to disciplined capital allocation. Abel is showing he is willing to simplify, concentrate, and reposition toward names he wants to own. The stock is down about 6% over the past year, but the company still carries a market cap above $1 trillion, giving investors a rare mix of stability and quiet change.
My Take For You: Berkshire is no longer just a Buffett legacy holding. It is becoming Abel’s portfolio, and the first moves suggest more active reshaping than some investors expected.
My Verdict: Buy this. The risk is that a more active portfolio style creates more second-guessing if the new bets underperform.
AI Shift (Sponsored)
Elon Musk could take SpaceX public in 2026, at an estimated $1.75 trillion valuation.
The IPO would include Elon's AI model, Grok. But according to Louis Navellier,
a radical new AI model will launch this year… over 1,000 times more powerful than Elon's.
And the company behind it could outperform SpaceX in the process.
Click here for full details (including Louis' new pick — free).
*This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.
Pharmaceuticals
Novo Nordisk Is Taking the Weight-Loss Fight Global
Novo Nordisk A/S (NYSE: NVO) is trying to shift the obesity-drug story beyond the U.S., and that matters after a difficult year for the stock. The company says it is preparing to go “all in” on launching its Wegovy pill outside America, with first international launches expected later this year pending approvals.
Management called the opportunity “major,” pointing to patient interest, doctor readiness, and telehealth partners as key market factors.
The timing is important. Novo still expects 2026 sales and profits to decline between 4% and 12%, pressured by lower U.S. prices and generic competition in markets such as India, Canada, Brazil, and China. But the Wegovy pill has already shown strong U.S. uptake, with total prescriptions above 2 million, and Novo says the pill is energizing the broader Wegovy brand.
The international market could be the next major battleground. Analysts have pointed to the U.K., Germany, and Denmark as likely early launch candidates, while telehealth could help expand access in markets where traditional treatment adoption has been slow.
Novo trades around 10.5x earnings, offers a dividend yield above 4%, and is still down more than 33% over the past year. That gives investors a cheaper entry into a company that still owns one of the most important drug franchises in the world.
My Take For You: Novo’s U.S. pricing pressure is real, but the global pill rollout gives the stock a new growth path investors may be underpricing.
My Verdict: Buy this. The risk is that international launches move slower than expected or pricing outside the U.S. limits the upside.
Poll: What's your first move when markets open on a Monday?
Movers and Shakers
POET Technologies [POET]: Premarket Move: +12%
POET is bouncing after a brutal selloff tied to its $400 million capital raise. The cash gives the company fuel for AI optical hardware, but the dilution is real. Investors are also staring at lawsuits, a CFO transition, and a business that did just $503,389 in Q1 revenue while still losing money.
The Lumilens deal is the big reason bulls are still interested. The initial order is worth $50 million, with potential purchases above $500 million over five years. That has to ramp cleanly, because right now the stock is priced for a future the company has not delivered yet.
My Take: Do not chase this bounce. POET is high-upside, but the dilution and legal risk make this a stock to trade carefully, not own blindly.
York Space Systems [YSS]: Premarket Move: +9%
York is rebounding after a sharp slide, but the headline risk is serious. A law firm has opened a potential securities fraud investigation tied to allegations from a short report, including claims about a lost defense contract, software delivery issues, and customer dissatisfaction.
The stock is now down hard from its highs and trades below analyst targets, so bargain hunters are stepping in. But legal and contract-quality questions hit right at the heart of the space-defense story.
My Take: Stay away until the company responds clearly. Cheap relative to targets does not matter if the contract risk gets worse.
Regeneron [REGN]: Premarket Move: -10%
Regeneron is getting hit because its Phase 3 fianlimab melanoma trial missed the primary endpoint. The study showed a 5.1-month numerical improvement in median progression-free survival, but it failed to reach statistical significance, and that is what matters in biotech.
The Street is cutting expectations fast. Citi downgraded the stock to neutral and slashed its target to $700 from $900, while BMO also cut its target after the update. For a major pipeline catalyst, this was a clear disappointment.
My Take: Do not buy the first dip. Regeneron is still a strong company, but this failed catalyst damages the near-term setup. Wait for the stock to find a real floor. Be ready to pounce, though.
Tech Shift (Sponsored)
Confirmed by satellites 300 miles above the Earth's surface...
Elon Musk is rolling out a breakthrough technology that could replace our need for foreign oil and ignite a $10 trillion boom for a small group of stocks.
Click here to learn how you can invest in this before it becomes mainstream.
Everything Else
🤖 AI stock picks are widening beyond the usual suspects, as investors look for the next wave of winners powering cloud infrastructure, chips, and enterprise growth behind the scenes.
🛢️ Oil is climbing again as Hormuz fears keep traders staring at the world’s most stressful shipping lane.
✈️ Ryanair warned that jet fuel costs could keep squeezing airlines, because cheap flights still run on expensive energy.
🏦 Mizuho shares rose after a report that it may invest in Rakuten Bank, which would add another twist to Japan’s digital banking race.
🧩 Tata Electronics and ASML are teaming up on India’s first chip fab, giving the country’s semiconductor ambitions a serious boost.
🌐 DayOne plans a dual Singapore-U.S. IPO, because the AI infrastructure boom apparently needs another public-market moment.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
